Elanco Animal Health (NYSE:ELAN) Issues Quarterly Earnings Results

Key Points

• Q1 beat and raised FY guidance: Elanco reported $0.40 EPS vs. $0.34 consensus and $1.37B revenue (≈15% YoY), and lifted FY‑2026 targets to 5–7% organic growth, adjusted EBITDA $975M–$1.005B and adjusted EPS $1.03–$1.09.
• Launch-driven innovation momentum: New products powered the quarter — Zenrelia reached blockbuster status in over 50% of U.S. clinics with >80% reorder rates and Credelio Quattro is in >40% of clinics, supporting a raised 2026 innovation revenue goal of $1.2B.
• Near-term risks and balance‑sheet focus: Management flagged FDA requests for additional Zenrelia data and margin headwinds from inventory/inflation and generics, while targeting net leverage of 3.0–3.2x this year (aiming <3x in 2027) and cost savings/automation to drive >$1B free cash flow by 2028.

Elanco Animal Health (NYSE:ELAN - Get Free Report) issued its earnings results on Wednesday. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.34 by $0.06, FiscalAI reports. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same period last year, the business posted $0.37 EPS. The company's revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health updated its Q2 2026 guidance to 0.250-0.285 EPS and its FY 2026 guidance to 1.030-1.090 EPS.

Here are the key takeaways from Elanco Animal Health's conference call:

• Raised guidance: Elanco increased full-year targets to 5%-7% organic growth, adjusted EBITDA of $975M–$1.005B, adjusted EPS of $1.03–$1.09, and raised its 2026 innovation revenue goal to $1.2B.
• Launch momentum: Innovation sales drove the quarter — Zenrelia reached blockbuster status and is now in >50% of U.S. clinics with >80% reorder rates, while Credelio Quattro is in >40% of clinics and has reached 53% share within those clinics, with rapid international rollout underway.
• Strong Q1 financials and deleveraging: Q1 revenue of $1.371B (10% organic growth) produced adjusted EBITDA of $334M (+21%) and EPS of $0.40, with net debt $3.3B (3.5x) and management tightening year-end net leverage guidance to 3.0–3.2x and targeting <3x in 2027.
• Key risks: The FDA has requested additional data for Zenrelia (company’s guidance assumes no U.S. label change), and management flagged near-term gross margin headwinds from inventory/inflation plus competitive/generic pressures that could push results toward the low end of guidance.
• Productivity program: The Elanco Ascend initiative (5,000+ projects) plus AI/automation is expected to drive margin expansion and operational efficiencies, enabling continued reinvestment in launches and a target of >$1B free cash flow through 2028.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock traded up $3.22 during trading hours on Wednesday, reaching $26.21. 12,364,331 shares of the stock traded hands, compared to its average volume of 4,989,493. The company has a 50 day moving average price of $23.82 and a 200 day moving average price of $23.29. The firm has a market capitalization of $13.03 billion, a price-to-earnings ratio of -54.60, a P/E/G ratio of 2.87 and a beta of 1.69. Elanco Animal Health has a one year low of $10.75 and a one year high of $27.72. The company has a quick ratio of 1.08, a current ratio of 2.17 and a debt-to-equity ratio of 0.60.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ELAN. Weiss Ratings upgraded Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a report on Monday, April 27th. Piper Sandler upgraded shares of Elanco Animal Health from a "neutral" rating to an "overweight" rating and upped their target price for the company from $24.00 to $30.00 in a research note on Thursday, January 22nd. UBS Group reaffirmed a "buy" rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Leerink Partners boosted their price objective on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an "outperform" rating in a report on Tuesday, February 24th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Elanco Animal Health currently has a consensus rating of "Moderate Buy" and an average price target of $27.90.

Key Stories Impacting Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q1 beat on both EPS and revenue — Elanco reported $0.40 EPS vs. consensus $0.34 and revenue of $1.37B (vs. ~$1.28B est.), with revenue up ~15% year‑over‑year. The print is the primary driver of the rally because it showed improving top‑line momentum and margin progression. Elanco Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised FY‑2026 guidance and innovation targets — Elanco lifted revenue, adjusted EBITDA and adjusted EPS (FY EPS raised to $1.03–$1.09) and improved its year‑end net leverage target, signaling stronger operating leverage and cash‑flow outlook. That upgrade supports a higher valuation multiple for the stock. Elanco Reports Q1 2026 Results and Raises Guidance
• Positive Sentiment: Product momentum: two products (Negasunt Powder and Tanidil) received emergency use authorizations, supporting near‑term revenue upside from innovation and validating R&D/launch execution. This likely boosted investor confidence in the growth story. Elanco Moves Higher on Earnings Strength and Product Momentum
• Neutral Sentiment: Analyst sentiment is constructive — coverage shows an average rating of “Moderate Buy,” which may support follow‑through buying but doesn’t imply unanimous bullishness. Analysts Give Elanco Moderate Buy Rating
• Negative Sentiment: Q2 EPS guidance came in slightly below consensus — Elanco gave Q2 EPS guidance of $0.250–$0.285 versus a street estimate near $0.290, which tempers the beat-and-raise message and could limit upside if investors focus on near‑term cadence rather than full‑year improvement. Q2 Guidance in Elanco Q1 Release

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Compound Planning Inc. raised its stake in shares of Elanco Animal Health by 29.7% in the fourth quarter. Compound Planning Inc. now owns 21,312 shares of the company's stock worth $482,000 after buying an additional 4,876 shares during the period. Invesco Ltd. grew its stake in shares of Elanco Animal Health by 336.0% during the 4th quarter. Invesco Ltd. now owns 4,789,037 shares of the company's stock valued at $108,376,000 after acquiring an additional 3,690,735 shares during the period. Corient Private Wealth LLC grew its stake in shares of Elanco Animal Health by 122.3% during the 4th quarter. Corient Private Wealth LLC now owns 165,381 shares of the company's stock valued at $3,743,000 after acquiring an additional 90,993 shares during the period. Mercer Global Advisors Inc. ADV increased its holdings in Elanco Animal Health by 29.0% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 78,610 shares of the company's stock worth $1,779,000 after acquiring an additional 17,657 shares in the last quarter. Finally, State of Tennessee Department of Treasury raised its stake in Elanco Animal Health by 8.1% during the 4th quarter. State of Tennessee Department of Treasury now owns 146,658 shares of the company's stock worth $3,532,000 after acquiring an additional 11,012 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.